US EditionPublished • loading... • Updated
Lilly in Talks to Buy Ventyx Biosciences for More than $1 ...
Eli Lilly's acquisition would add treatments for autoimmune and neurodegenerative diseases, with Ventyx shares jumping over 60% after the $1 billion-plus deal news.
- On Tuesday, the Wall Street Journal reported Eli Lilly is in advanced talks to acquire Ventyx Biosciences for more than $1 billion and said an announcement could be imminent.
- To strengthen its autoimmune and metabolic offerings, Lilly would add Ventyx's oral programmes, including NLRP3 inhibitors targeting inflammation and tamuzimod for ulcerative colitis and Parkinson's.
- Shares of Ventyx Biosciences jumped 62.59% to $16.34 in after-hours trading on Tuesday, despite a market capitalization about $717.2 million, highlighting a valuation gap for the $1 billion-plus deal.
- It would also narrow Lilly's competitive gap with Novo Nordisk by reportedly including NLRP3 inhibitors and follows Amgen's reported $840 million deal, potentially boosting 2026 M&A momentum.
- October trial results showed a substantial biomarker reduction for VTX3232, an interim analysis is due in the first quarter of this year, and Daniel Skovronsky said `There is increasing evidence that inflammation is a key driver of many chronic diseases`.
Insights by Ground AI
39 Articles
39 Articles
Ventyx (VTYX) Shares Soar 62.5% Overnight, Here's What's Going On With This Trending Stock - Eli Lilly (NYSE:LLY), Novo Nordisk (NYSE:NVO)
Ventyx shares jumped in after-hours trading following reports that Eli Lilly is in advanced talks to acquire the biopharma company for over $1 billion.
·New York, United States
Read Full Article
Coverage Details
Total News Sources39
Leaning Left4Leaning Right0Center14Last UpdatedBias Distribution78% Center
Bias Distribution
- 78% of the sources are Center
78% Center
L 22%
C 78%
Factuality
To view factuality data please Upgrade to Premium
